BEAT
HeartBeam, Inc.
Medical - Healthcare Information Services
Market Cap$34M
5Y Perf.-76.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BEAT vs IDXX
Revenue, margins, valuation, and 5-year total return — side by side.
IDXX
IDEXX Laboratories, Inc.
Medical - Diagnostics & Research
Market Cap$46.12B
5Y Perf.-4.7%
BEAT vs IDXX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BEAT | IDXX |
|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Diagnostics & Research |
| Market Cap | $34M | $46.12B |
| Revenue (TTM) | $0.00 | $4.45B |
| Net Income (TTM) | $-21M | $1.10B |
| Gross Margin | — | 62.1% |
| Operating Margin | — | 31.6% |
| Forward P/E | — | 39.9x |
| Total Debt | $0.00 | $1.08B |
| Cash & Equiv. | $4M | $180M |
BEAT vs IDXX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BEAT
IDXX
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| HeartBeam, Inc. (BEAT) | 100 | 24.0 | -76.0% |
| IDEXX Laboratories,… (IDXX) | 100 | 95.3 | -4.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BEAT vs IDXX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IDXX leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. HeartBeam, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
BEAT
HeartBeam, Inc.
The Income Pick
BEAT is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.24
- Lower volatility, beta 1.24
- Beta 1.24
Best for: income & stability and sleep-well-at-night
IDXX
IDEXX Laboratories, Inc.
The Growth Play
IDXX carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 10.4%, EPS growth 22.6%, 3Y rev CAGR 8.5%
- 5.7% 10Y total return vs BEAT's -81.7%
- 10.4% revenue growth vs BEAT's -100.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IDXX | 10.4% revenue growth vs BEAT's -100.0% |
| Stability / Safety | BEAT | Beta 1.24 vs IDXX's 1.35 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IDXX | +22.3% vs BEAT's -53.5% |
| Efficiency (ROA) | IDXX | 32.6% ROA vs BEAT's -353.1% |
BEAT vs IDXX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2019
FY 2025
BEAT vs IDXX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBEATLAGGINGIDXX
IDXXIDEXX Laboratories, I…
2leads
BEATHeartBeam, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs IDXXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BEAT1/1
Valuation MetricsMultiples, price ratios, and targets
BEAT2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IDXX4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
IDXX6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BEAT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IDXX and BEAT operate at a comparable scale, with $4.4B and $0 in trailing revenue.
| Metric | BEATHeartBeam, Inc. | IDXXIDEXX Laboratorie… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $4.4B |
| EBITDAEarnings before interest/tax | -$21M | $1.5B |
| Net IncomeAfter-tax profit | -$21M | $1.1B |
| Free Cash FlowCash after capex | -$15M | $845M |
| Gross MarginGross profit ÷ Revenue | — | +62.1% |
| Operating MarginEBIT ÷ Revenue | — | +31.6% |
| Net MarginNet income ÷ Revenue | — | +24.6% |
| FCF MarginFCF ÷ Revenue | — | +19.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +14.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +22.2% | +16.6% |
BEAT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
BEAT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | BEATHeartBeam, Inc. | IDXXIDEXX Laboratorie… |
|---|---|---|
| Market CapShares × price | $34M | $46.1B |
| Enterprise ValueMkt cap + debt − cash | $30M | $47.0B |
| Trailing P/EPrice ÷ TTM EPS | -1.38x | 44.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 39.94x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.10x |
| EV / EBITDAEnterprise value multiple | — | 32.06x |
| Price / SalesMarket cap ÷ Revenue | — | 10.72x |
| Price / BookPrice ÷ Book value/share | 11.09x | 29.11x |
| Price / FCFMarket cap ÷ FCF | — | 43.78x |
BEAT leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
IDXX leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
IDXX delivers a 70.9% return on equity — every $100 of shareholder capital generates $71 in annual profit, vs $-6 for BEAT. On the Piotroski fundamental quality scale (0–9), IDXX scores 7/9 vs BEAT's 1/9, reflecting strong financial health.
| Metric | BEATHeartBeam, Inc. | IDXXIDEXX Laboratorie… |
|---|---|---|
| ROE (TTM)Return on equity | -5.7% | +70.9% |
| ROA (TTM)Return on assets | -3.5% | +32.6% |
| ROICReturn on invested capital | — | +42.5% |
| ROCEReturn on capital employed | -4.6% | +61.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 7 |
| Debt / EquityFinancial leverage | — | 0.67x |
| Net DebtTotal debt minus cash | -$4M | $897M |
| Cash & Equiv.Liquid assets | $4M | $180M |
| Total DebtShort + long-term debt | $0 | $1.1B |
| Interest CoverageEBIT ÷ Interest expense | — | 35.55x |
IDXX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
IDXX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IDXX five years ago would be worth $10,864 today (with dividends reinvested), compared to $1,825 for BEAT. Over the past 12 months, IDXX leads with a +22.3% total return vs BEAT's -53.5%. The 3-year compound annual growth rate (CAGR) favors IDXX at 6.1% vs BEAT's -26.2% — a key indicator of consistent wealth creation.
| Metric | BEATHeartBeam, Inc. | IDXXIDEXX Laboratorie… |
|---|---|---|
| YTD ReturnYear-to-date | -64.8% | -13.5% |
| 1-Year ReturnPast 12 months | -53.5% | +22.3% |
| 3-Year ReturnCumulative with dividends | -59.8% | +19.3% |
| 5-Year ReturnCumulative with dividends | -81.7% | +8.6% |
| 10-Year ReturnCumulative with dividends | -81.7% | +568.9% |
| CAGR (3Y)Annualised 3-year return | -26.2% | +6.1% |
IDXX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BEAT and IDXX each lead in 1 of 2 comparable metrics.
Risk & Volatility
BEAT is the less volatile stock with a 1.24 beta — it tends to amplify market swings less than IDXX's 1.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IDXX currently trades 75.2% from its 52-week high vs BEAT's 21.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BEATHeartBeam, Inc. | IDXXIDEXX Laboratorie… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.35x |
| 52-Week HighHighest price in past year | $4.00 | $769.98 |
| 52-Week LowLowest price in past year | $0.54 | $465.00 |
| % of 52W HighCurrent price vs 52-week peak | +21.4% | +75.2% |
| RSI (14)Momentum oscillator 0–100 | 34.2 | 45.0 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 531K |
Evenly matched — BEAT and IDXX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | BEATHeartBeam, Inc. | IDXXIDEXX Laboratorie… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $773.13 |
| # AnalystsCovering analysts | — | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.6% |
Insufficient data to determine a leader in this category.
Key Takeaway
BEAT leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). IDXX leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallHeartBeam, Inc. (BEAT)Leads 2 of 6 categories
Loading custom metrics...
BEAT vs IDXX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BEAT or IDXX a better buy right now?
IDEXX Laboratories, Inc.
(IDXX) offers the better valuation at 44. 3x trailing P/E (39. 9x forward), making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BEAT or IDXX?
Over the past 5 years, IDEXX Laboratories, Inc.
(IDXX) delivered a total return of +8. 6%, compared to -81. 7% for HeartBeam, Inc. (BEAT). Over 10 years, the gap is even starker: IDXX returned +568. 9% versus BEAT's -81. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BEAT or IDXX?
By beta (market sensitivity over 5 years), HeartBeam, Inc.
(BEAT) is the lower-risk stock at 1. 24β versus IDEXX Laboratories, Inc. 's 1. 35β — meaning IDXX is approximately 9% more volatile than BEAT relative to the S&P 500.
04Which is growing faster — BEAT or IDXX?
On earnings-per-share growth, the picture is similar: IDEXX Laboratories, Inc.
grew EPS 22. 6% year-over-year, compared to 15. 1% for HeartBeam, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BEAT or IDXX?
IDEXX Laboratories, Inc.
(IDXX) is the more profitable company, earning 24. 6% net margin versus 0. 0% for HeartBeam, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus 0. 0% for BEAT. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BEAT or IDXX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BEAT or IDXX better for a retirement portfolio?
For long-horizon retirement investors, IDEXX Laboratories, Inc.
(IDXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+568. 9% 10Y return). Both have compounded well over 10 years (IDXX: +568. 9%, BEAT: -81. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BEAT and IDXX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.